This post was originally published on this site
First-round bids kicked off this week, and bidders included private equity firm Clayton Dubilier & Rice.
The report added that Reckitt Benckiser’s unit could be worth around $7 billion in a sale, citing bankers.
The sale comes as the infant-formula industry has been rocked by shortages that have spread to the U.S., exasperated by a shutdown of a Sturgis, Michigan plant by rival Abbott (NYSE:ABT) amid concerns of contamination.
